KLRS compared with CHRS: revenue, margins and what each company keeps, and the suppliers and customers both name

KLRSKalaris Therapeutics, Inc.

Mkt capRevenueRevenue

CHRSCoherus Oncology, Inc.

Mkt capRevenueRevenue

Compare

KLRSKalaris Therapeutics, Inc.

CHRSCoherus Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

KLRSKalaris Therapeutics, Inc.

2.00▼−1.48%· post 2.06· delayed

Mkt cap$48.3MRevenue—Revenue—

CHRSCoherus Oncology, Inc.

0.87▲+5.32%· post 0.77· delayed

After hoursNov 2 '26delayed

Mkt cap$128.3MRevenue$14MQ2 FY26Revenue$42MFY25

Compare

After hoursNov 2 '26delayed

KLRSKalaris Therapeutics, Inc.

CHRSCoherus Oncology, Inc.

2.00▼−1.48%post 2.06delayed

Price

0.87▲+5.32%post 0.77delayed

$48.3M

Mkt cap

$128.3M

—

Revenue

$14MQ2 FY26

—

Revenue

$42MFY25

KLRS2.00▼−1.48%vsCHRS0.87▲+5.32%After hoursNov 2 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KLRS: latest quarter not drawable. CHRS: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KLRS 0

None

Shared 0

No disclosed counterparties: KLRS.

Only CHRS 8

GSKGlaxoSmithKlinesupplier

INOInovio Pharmaceuticalscustomer

—Junshi Biosciencesunlistedsupplier

—Janssen Research & Developmentunlistedsupplier

4 more · CHRS chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

KLRS, solidCHRS, dashed